© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.
Treating Alzheimer disease presents a spiderweb of complexity for physicians, and its intricacies have made assessing therapies equally puzzling.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive look into the discussion surrounding aducanumab and how it reflects the challenges of conducting clinical trials in Alzheimer disease.
January 21, 2021
The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.
January 20, 2021
Hippocampal-sparing and limbic-predominant atrophy were also associated with incident dementia, with faster cognitive decline in the limbic predominant atrophy group.
The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine detailed his study on the correlations between sleep and cognitive decline in middle-aged Hispanics.
January 19, 2021
New technology enables the collection and analysis of speech behaviors, but this requires an extensive database, which the ADDF seeks to help develop.
Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%, according to Abbott, the test’s developer.
January 18, 2021
Here's what is coming soon to NeurologyLive.
January 16, 2021
Maha Radhakrishnan, MD, the Group SVP and chief medical officer at Biogen, discussed the collaborative study between Biogen and Apple that’s expected to kick off later this year.
Neurology News Network for the week ending January 16, 2021.
January 15, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.
January 14, 2021
The findings suggest and confirm previous studies that suggested plasma p-tau181 may be used as a measure to monitor Alzheimer disease progression in clinical practice and treatment trials.